Table 2.
Non-invasive vagus nerve stimulation using the gammaCore® device in chronic cluster headache.
| BASELINE Mean (SD) Median (IQR) |
3 months Mean (SD) Median (IQR) |
Mean difference (95% CI) | p value* | |
|---|---|---|---|---|
| Frequency (attacks/month) | 124 (±67) 107 (65–174) |
79 (±63) 65 (33–120) |
−44.7 (−25.1 to −64.3) | <0.001 |
| Severity (VRS) | 8 (±2) 8 (7–10) |
7 (±3) 7 (5–9) |
−1.2 (−0.2 to −1.9) | 0.001 |
| Duration (minutes) | 86 (±58) 68 (49–103) |
75 (±64) 63 (35–100) |
−10.5 (−0.15 to −20.9) | 0.046 |
| HIT-6 | 65 (±7) 65 (62–71) |
62 (±10) 64 (58–67) |
−3.3 (−0.9 to −5.7) | 0.009 |
| Triptan use (4 weeks) | 32 (±36) 21 (0–56) |
23 (±34) 7 (0–42) |
−9.0 (−1.2 to −16.8) | 0.024 |
| Oxygen use (4 weeks) | 46 (±62) 16 (0–82) |
32 (±52) 8 (0–55) |
−13.5 (0.1 to −27.0) | 0.051 |
*
The threshold for statistical significance based on Bonferroni adjustment is 0.008 (i.e., 0.05/6); SD, standard deviation; CI, confidence interval; HIT-6, Headache impact test – 6; VRS, Verbal Rating Score (0 = no pain;10 = excruciating pain).